PTGS2 and viral infectious disease: Extrapolating results from ROS and COX-2 assays presented in the study led to the suggestion that protective PHT-MLT doses which may prevent and counteract viral infections, could be as high as 5.0 mg to 50 mg per day for symptomatic adult human subjects, as suggested by Loh [7].